Full-Time
Director – Portfolio Performance Solutions
Biomedical AI research software
Senior, Expert
Toronto, ON, Canada
- Critical thinking and can identify the core value drivers driving disproportional impact
- Experience facilitating high-level/executive discussions in the healthcare and pharma space and an understanding of R&D priorities
- Stakeholder management skills and ability to work cross-functionally
- Create impactful stories with complex qualitative and quantitative information
- 7+ years of healthcare or pharma experience
- Management consulting experience at a top consulting firm is nice to have
- Identify the impact of BenchSci's ASCEND platform on accelerating discovery, early-stage research and translational optimization at our global pharmaceutical customers
- Translate the scientific impact and insights (e.g., target discovery, risk identification, experimental path optimization, translational path enhancement) to economic value creation for R&D programs powered by the ASCEND platform
- Define the path to evaluating value creation for the entire R&D portfolio that reflects value creation through the acceleration of specific ongoing R&D programs and the discovery of new opportunities
- Be a partner to scientific and portfolio leadership at our partner organizations and deliver insightful reports and presentations to leading R&D executives
- Present at customer leadership meetings to help them understand their R&D portfolio performance
- Lead business analysts to develop a suite of R&D portfolio analytics that diagnose efficiency improvement opportunities
- Work with our Science, Delivery, and Analytics teams to analyze internal customer data and define value stories
- Be a thoughtful operator and define the path to scaling up value assessment for your team
BenchSci's mission is to exponentially increase the speed and quality of life-saving research by empowering scientists with the world's most advanced biomedical artificial intelligence. The company is currently building on their success with antibodies to address other critical reagents—including recombinant proteins, siRNAs, and CRISPR tools—as well as model systems such as animal models and cell lines.
Company Stage
Series D
Total Funding
$169.7M
Headquarters
Toronto, Canada
Founded
2015
6 month growth
↓ -12%1 year growth
↓ -6%2 year growth
↑ 43%Benefits
Remote-first culture
Equity options
15 days vacation + additional day every year
Unlimited flex time
Comprehensive health & dental benefits
Psychotherapist services
Annual Learning & Development budget
Home office set-up budget
Wellness, lifestyle & productivity spending account